March 4, 2026 · Form 4 insider transaction
Torley Helen sold 7,329 shares of Halozyme Therapeutics, Inc. at $69.94 per share, a transaction worth $512.6K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 0 days after the transaction.
The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.; Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.400 to $70.390. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.